On 29 May 2019, orphan designation (EU/3/19/2162) was granted by the European Commission to Pharma Gateway AB, Sweden, for emixustat hydrochloride for the treatment of Stargardt’s disease.
|Disease / condition||
Treatment of Stargardt's disease
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: